A look at the shareholders of Checkpoint Therapeutics, Inc. ( NASDAQ:CKPT) can tell us which group is most powerful. With 56% stake, individual investors possess the maximum shares in the company. In ...

James F. Oliviero III, the CEO, President, and Director of Checkpoint Therapeutics , Inc. (NASDAQ:CKPT), recently sold shares ...

LifeVantage has higher revenue and earnings than Checkpoint Therapeutics. Checkpoint Therapeutics is trading at a lower price-to-earnings ratio than LifeVantage, indicating that it is currently ...

William Garrett Gray, the Chief Financial Officer of Checkpoint Therapeutics , Inc. (NASDAQ:CKPT), recently sold 74,110 shares of the company’s common stock. The shares were sold at a weighted average ...

Market OverviewThe Global Breast Cancer Therapeutics Market  remains one of the most prevalent forms of cancer worldwide, ...

On Tuesday, H.C. Wainwright maintained its Buy rating and $34.00 stock price target for Checkpoint Therapeutics (NASDAQ:CKPT). This affirmation follows Checkpoint Therapeutics' ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on QuidelOrtho (QDEL – Research Report) and Palatin ...